journal article·2023-07Open access

Structure-function-guided design of synthetic peptides with anti-infective activity derived from wasp venom

Andreia Boaro, Lucía Ageitos, Marcelo Der Torossian Torres, Esther Broset Blasco, Sebahat Oztekin, Cesar de la Fuente-Nunez

Cell Reports Physical Science· Volume 4· Issue 7

Abstract

Antimicrobial peptides (AMPs) derived from natural toxins and venoms offer a promising alternative source of antibiotics. Here, through structure-function-guided design, we convert two natural AMPs derived from the venom of the solitary eumenine wasp Eumenes micado into α-helical AMPs with reduced toxicity that kill Gram-negative bacteria in vitro and in a preclinical mouse model. To identify the sequence determinants conferring antimicrobial activity, an alanine scan screen and strategic single lysine substitutions are made to the amino acid sequence of these natural peptides. These efforts yield a total of 34 synthetic derivatives, including alanine substituted and lysine-substituted sequences with stabilized α-helical structures and increased net positive charge. The resulting lead synthetic peptides kill the Gram-negative pathogens Escherichia coli and Pseudomonas aeruginosa (PAO1 and PA14) by rapidly permeabilizing both their outer and cytoplasmic membranes, exhibit anti-infective efficacy in a mouse model by reducing bacterial loads by up to three orders of magnitude, and do not readily select for bacterial resistance.
Source: openalex_inverted_index · Quality: baseline

Research context

OpenAlex topics: Antimicrobial Peptides and Activities · Biochemical and Structural Characterization · Nicotinic Acetylcholine Receptors Study

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

References (80)

Show source-provided references
1. Centers for Disease control and prevention Unit, C. for D.C. and P. (U. S.., (U.S.), N.C. for E.Z. and I.D., and Strategy, D. of H.Q.P.A.R.C. and S.U. (2019). Antibiotic Resistance Threats in the United States, 2019. CDC, 114.
2. Trends in peptide drug discovery10.1038/s41573-020-00135-8 ↗
3. Structure-function-guided exploration of the antimicrobial peptide polybia-CP identifies activity determinants and generates synthetic therapeutic candidates10.1038/s42003-018-0224-2 ↗
4. Repurposing a peptide toxin from wasp venom into antiinfectives with dual antimicrobial and immunomodulatory properties10.1073/pnas.2012379117 ↗
5. Novel designed VmCT1 analogs with increased antimicrobial activity10.1016/j.ejmech.2016.11.040 ↗
6. Decoralin analogs with increased resistance to degradation and lower hemolytic activity10.1002/slct.201601590 ↗
7. Biologically active peptides from venoms: applications in antibiotic resistance, cancer, and beyond10.3390/ijms232315437 ↗
8. Peptide design principles for antimicrobial applications10.1016/j.jmb.2018.12.015 ↗
9. Synthetic biology and computer-based frameworks for antimicrobial peptide discovery10.1021/acsnano.0c09509 ↗
10. Mining for encrypted peptide antibiotics in the human proteome10.1038/s41551-021-00801-1 ↗
11. Bacterial biofilms: from the Natural environment to infectious diseases10.1038/nrmicro821 ↗
12. New mastoparan peptides in the venom of the solitary eumenine wasp Eumenes micado10.3390/toxins11030155 ↗
13. DBAASP: database of antimicrobial activity and structure of peptides10.1111/1574-6968.12489 ↗
14. The hydrophobic moment detects periodicity in protein hydrophobicity10.1073/pnas.81.1.140 ↗
15. HELIQUEST: a web server to screen sequences with specific α-helical properties10.1093/bioinformatics/btn392 ↗
16. Factors affecting the physical stability (aggregation) of peptide therapeutics10.1098/rsfs.2017.0030 ↗
17. Amphiphilicity index of polar amino acids as an aid in the characterization of amino acid preference at membrane-water interfaces10.1093/bioinformatics/18.4.608 ↗
18. Trifluoroethanol and colleagues: cosolvents come of age. Recent studies with peptides and proteins10.1017/S003358359800345X ↗
19. Mechanism of helix induction by trifluoroethanol: a framework for extrapolating the helix-forming properties of peptides from trifluoroethanol/water mixtures back to water10.1021/bi9707133 ↗
20. On the theory of helix—coil transition in polypeptides10.1063/1.1731802 ↗
21. A helix propensity scale based on experimental studies of peptides and proteins10.1016/S0006-3495(98)77529-0 ↗
22. Wasp venom peptide as a new antichagasic agent10.1016/j.toxicon.2020.04.099 ↗
23. Antimicrobial and antibiofilm activities of helical antimicrobial peptide sequences incorporating metal-binding motifs10.1021/acs.biochem.9b00440 ↗
24. Computer-aided design of mastoparan-like peptides enables the generation of nontoxic variants with extended antibacterial properties10.1021/acs.jmedchem.9b00915 ↗
25. Peptide design enables reengineering of an inactive wasp venom peptide into synthetic antiplasmodial agents10.1002/slct.201800529 ↗
26. The different interactions of lysine and arginine side chains with lipid membranes10.1021/jp405418y ↗
27. The vast structural diversity of antimicrobial peptides10.1016/j.tips.2019.04.012 ↗
28. Structure-activity relationship of mastoparan analogs: effects of the number and positioning of Lys residues on secondary structure, interaction with membrane-mimetic systems and biological activity10.1016/j.peptides.2015.04.021 ↗
29. Pseudomonas aeruginosa: all roads lead to resistance10.1016/j.tim.2011.04.005 ↗
30. Allison · 2015 · 583
31. Autonomous treatment of bacterial infections in vivo using antimicrobial micro- and nanomotors10.1021/acsnano.1c11013 ↗
32. In Vitro activities of membrane-active peptides alone and in combination with clinically used antimicrobial agents against stenotrophomonas maltophilia10.1128/AAC.44.6.1716-1719.2000 ↗
33. In-vitro activity and killing effect of polycationic peptides on methicillin-resistant Staphylococcus aureus and interactions with clinically used antibiotics10.1016/S0732-8893(00)00175-9 ↗
34. Combination studies between polycationic peptides and clinically used antibiotics against Gram-positive and Gram-negative bacteria10.1016/S0196-9781(00)00254-0 ↗
35. Expression of 4kD scorpion defensin and its in vitro synergistic activity with conventional antibiotics10.1007/s11274-012-1181-4 ↗
36. The human male reproductive tract antimicrobial peptides of the HE2 family exhibit potent synergy with standard antibiotics10.1002/psc.1246 ↗
37. Structural features governing the activity of lactoferricin-derived peptides that act in synergy with antibiotics against Pseudomonas aeruginosa in vitro and in vivo structural features governing the activity of lactoferricin-derived peptides that act in10.1128/AAC.00904-10 ↗
38. Azithromycin synergizes with cationic antimicrobial peptides to exert bactericidal and therapeutic activity against highly multidrug-resistant gram-negative bacterial pathogens10.1016/j.ebiom.2015.05.021 ↗
39. A lack of synergy between membrane-permeabilizing cationic antimicrobial peptides and conventional antibiotics10.1016/j.bbamem.2014.09.010 ↗
40. Short antibacterial peptides and erythromycin act synergically against Escherichia coli10.1093/jac/48.2.203 ↗
41. Ciprofloxacin: Chemistry, mechanism of action, resistance, antimicrobial spectrum, pharmacokinetics, clinical trials, and adverse reactions10.1002/j.1875-9114.1988.tb04058.x ↗
42. Coatable and resistance-proof ionic liquid for pathogen eradication10.1021/acsnano.0c07642 ↗
43. Zinc blockade of SOS response inhibits horizontal transfer of antibiotic resistance genes in enteric bacteria10.3389/fcimb.2018.00410 ↗
44. Mechanisms of ciprofloxacin resistance in Pseudomonas aeruginosa : new approaches to an old problem10.1099/jmm.0.000873 ↗
45. Drug resistance Biofilms as a mechanism of bacterial resistance10.1016/j.ddtec.2014.02.003 ↗
46. Comparing treatment strategies to reduce antibiotic resistance in an in vitro epidemiological setting10.1073/pnas.2023467118 ↗
47. Mechanism of interaction of different classes of cationic antimicrobial peptides with planar bilayers and with the cytoplasmic membrane of Escherichia coli10.1021/bi9826299 ↗
48. Persistent infection with Pseudomonas aeruginosa in ventilator-associated pneumonia10.1164/rccm.200802-239OC ↗
49. The contribution of Pseudomonas aeruginosa virulence factors and host factors in the establishment of urinary tract infections10.1093/femsle/fnx124 ↗
50. Community acquired fulminant Pseudomonas infection of the gastrointestinal tract in previously healthy infants10.1046/j.1440-1754.1998.00290.x ↗
51. Treatment of skin and soft tissue infections caused by Pseudomonas aeruginosa—a review of our experiences with citric acid over the past 20 years10.1016/j.wndm.2017.09.005 ↗
52. Relevance of multidrug-resistant Pseudomonas aeruginosa infections in cystic fibrosis10.1016/j.ijmm.2017.07.004 ↗
53. In vivo therapeutic efficacy of frog skin-derived peptides against Pseudomonas aeruginosa-induced pulmonary infection10.1038/s41598-017-08361-8 ↗
54. Renal transport of antibiotics and nephrotoxicity: a review10.1179/joc.2001.13.5.461 ↗
55. Membrane lipid composition : effect on membrane and organelle structure , function and compartmentalization and therapeutic avenues10.3390/ijms20092167 ↗
56. Basis for selectivity of cationic antimicrobial peptides for bacterial versus mammalian membranes10.1074/jbc.M507042200 ↗
57. Computer-aided design of antimicrobial peptides: are we generating effective drug candidates?10.3389/fmicb.2019.03097 ↗
58. Identification of novel cryptic multifunctional antimicrobial peptides from the human stomach enabled by a computational-experimental platform10.1021/acssynbio.8b00084 ↗
59. In silico optimization of a guava antimicrobial peptide enables combinatorial exploration for peptide design10.1038/s41467-018-03746-3 ↗
60. In vivo evaluation of polymeric micellar paclitaxel formulation : toxicity and efficacy10.1016/S0168-3659(01)00275-9 ↗
61. Defining body-weight reduction as a humane endpoint : a critical appraisal10.1177/0023677219883319 ↗
62. Mouse models of acute, chemical itch and pain in humans10.1111/j.1600-0625.2011.01367.x ↗
63. Behavioral differentiation between itch and pain in mouse10.1016/j.pain.2008.08.002 ↗
64. A cutback in Imiquimod cutaneous toxicity; comparative cutaneous toxicity analysis of Imiquimod nanotransethosomal gel with 5% marketed cream on the BALB/c mice10.1038/s41598-022-18671-1 ↗
65. Evaluation of skin irritation and acute and subacute oral toxicity of lavandula angustifolia essential oils in rabbit and mice
66. Minimization of local and systemic adverse effects of topical glucocorticoids by nanoencapsulation : in vivo safety of hydrocortisone – hydroxytyrosol loaded chitosan nanoparticles10.1002/jps.24666 ↗
67. Selective antibacterial activity of the cationic peptide PaDBS1R6 against Gram-negative bacteria10.1016/j.bbamem.2019.03.016 ↗
68. Bacterial biofilm development as a multicellular adaptation: antibiotic resistance and new therapeutic strategies10.1016/j.mib.2013.06.013 ↗
69. Therapeutic potential of venom peptides10.1038/nrd1197 ↗
70. Analogs of the scorpion venom peptide stigmurin : structural assessment , toxicity , and increased antimicrobial activity10.3390/toxins10040161 ↗
71. Activity of novel synthetic peptides against Candida albicans10.1038/srep09657 ↗
72. Modulation of magainin 2 - lipid bilayer interactions by peptide charge10.1021/bi961870p ↗
73. Design of potent , non-toxic antimicrobial agents based upon the naturally occurring frog skin peptides , ascaphin-8 and peptide XT-710.1111/j.1747-0285.2008.00671.x ↗
74. Agar and broth dilution methods to determine the minimal inhibitory concentration (MIC) of antimicrobial substances10.1038/nprot.2007.521 ↗
75. Compounds which increase the permeability of the Pseudomonas aeruginosa outer membrane10.1128/AAC.26.1.48 ↗
76. Interactions of bacterial cationic peptide antibiotics with outer and cytoplasmic membranes of Pseudomonas aeruginosa10.1128/AAC.44.12.3317-3321.2000 ↗
77. A polytherapy based approach to combat antimicrobial resistance using cubosomes10.1038/s41467-022-28012-5 ↗
78. Antibacterial activity and antibiotic-enhancing effects of honeybee venom against methicillin-resistant staphylococcus aureus10.3390/molecules21010079 ↗
79. Synergy, antagonism, and what the chequerboard puts between them10.1093/jac/dkg301 ↗
80. DBAASP v3: database of antimicrobial/cytotoxic activity and structure of peptides as a resource for development of new therapeutics10.1093/nar/gkaa991 ↗